Cargando…
The Burden of Short-Acting β(2)-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program
INTRODUCTION: Preliminary results from the SABINA (SABA use IN Asthma) program showed lower overuse of short-acting β(2)-agonist (SABA) in Italy compared to other European countries. The aim of the present study was to ascertain whether SABINA’s results might have been affected by the Italian Nation...
Autores principales: | Di Marco, Fabiano, D’Amato, Mariella, Lombardo, Francesco P., Micheletto, Claudio, Heiman, Franca, Pegoraro, Valeria, Boarino, Silvia, Manna, Giandomenico, Mastromauro, Francesca, Spennato, Simona, Papi, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280008/ https://www.ncbi.nlm.nih.gov/pubmed/34043208 http://dx.doi.org/10.1007/s12325-021-01772-0 |
Ejemplares similares
-
SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020) -
Short-acting β(2)-agonists and exacerbations in children with asthma in England: SABINA Junior
por: Morgan, Ann, et al.
Publicado: (2023) -
Healthcare costs associated with short-acting β(2)-agonists in asthma: observational UK SABINA study
por: Attar-Zadeh, Darush, et al.
Publicado: (2023) -
Short-acting β(2)-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III
por: Yorgancıoğlu, Arzu, et al.
Publicado: (2022) -
Short-acting β(2)-agonist prescription patterns for asthma management in the SABINA III primary care cohort
por: Price, David, et al.
Publicado: (2022)